TY - JOUR T1 - Increased disease severity and mortality associated with the Bronchiectasis-GORD phenotype JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2015.PA366 VL - 46 IS - suppl 59 SP - PA366 AU - Melissa McDonnell AU - O'Mahony Michael AU - Breen David AU - O'Regan Anthony AU - Rutherford Robert Y1 - 2015/09/01 UR - http://erj.ersjournals.com/content/46/suppl_59/PA366.abstract N2 - Background: Symptomatic gastro-oesophageal reflux disease (GORD) has been associated with increased exacerbations and reduced quality of life in bronchiectasis (BR). We aimed to evaluate the prevalence of a BR-GORD phenotype, utilising the multi-domain Bronchiectasis Severity Index (BSI), to determine associations with disease severity and mortality.Methods: A retrospective cohort study in 212 consecutive BR patients attending our institution over a 2-year period was performed. A diagnosis of GORD was based on standardised definitions following full review of electronic records, review of prescriptions and investigator definitions.Results: 72 (19.8%) BR patients were confirmed to have co-existent GORD treated with proton pump inhibitors. These patients were predominantly male, older and with higher BMIs than their counterparts (p=<0.001, 0.002 and 0.038 respectively). Significant symptom associations included cough (p=0.002), daily sputum production (p=0.040) and wheeze (p<0.001). Exacerbation frequency (p=0.011), number of hospitalisations (p=0.022), no. of lobes affected (p<0.001), cystic disease (p=0.006), Pseudomonas colonisation (p=0.017) and no. of microbes cultured on follow up (p=0.008) were significantly higher in the BR-GORD group leading to higher BSI scores (p=0.004) and increased mortality (p=0.026). Logistic regression analysis showed BSI (OR 2.2, 95% CI 1.1-6.7) and mortality (OR 2.5, 95% CI 1.1-7.8) to be independently associated with the BR-GORD phenotype.Conclusion: BR-GORD patients have an increased disease severity and mortality risk compared with BR patients without GORD. Increased recognition of this BR-GORD phenotype and its potential for targeted therapy is needed. ER -